Page 5 - Agvhd News Today

Dr Pashna Munshi describes for what myeloid malignancies allogeneic transplantation is indicated, and its curative potential.

Pashna Munshi, MD, presents the patient profile of a 44-year-old woman with acute myeloid leukemia diagnosed with grade 2 skin acute GVHD, and shares her initial impressions and what she might have done differently.

Low-vol ETF LVHD recently signaled a buy according to one key indicator, and could be an interesting option amid ongoing market volatility.

Dr Nelson J. Chao presents the patient profile of a 67-year-old woman with chronic graft-versus-host disease after a bone marrow donation from a multiparous female.

Drs Yi-Bin Chen and Sophie Paczesny review the diagnosis and staging of both acute and chronic GVHD, and the challenges clinicians may encounter.

Nelson J. Chao, MD, MBA, explains the frontline treatment options for chronic GVHD, and when to consider restarting an immunosuppressive regimen.

Yi-Bin Chen, MD, shares the most common GVHD prophylaxis regimens, and which regimen he typically chooses for his patients with GVHD.

Dr Sophie Paczesny details the incidence of graft versus host disease (GVHD) in patients receiving allogeneic transplants, and Dr Yi-Bin Chen describes the differing risk factors for acute and chronic GVHD.

Sophie Paczesny, MD, PhD, explains which malignancies allogeneic transplantation can be used as a potentially curative treatment approach, and which patients are best suited for transplant.

Dr Nelson J. Chao reviews how chronic graft-versus-host disease is diagnosed and staged, and the importance of multidisciplinary team communication.